SMO and basal cell carcinoma: Second generation Smo inhibitors, including Itraconazole and arsenic trioxide, both inhibit the growth of medulloblastoma and basal cell carcinoma, prolonging survival of mice with intracranial drug-resistant Smo [59, 60].